ACM
GILD icon

AlphaCrest Capital Management’s Gilead Sciences GILD Stock Holding History

AlphaCrest Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-110,669
Closed -$7.19M – 1113
2019
Q4 		$7.19M Sell
110,669
-60,432
-35% -$3.94M 0.59% 10
2019
Q3 		$10.8M Buy
171,101
+113,178
+195% +$7.4M 0.66% 2
2019
Q2 		$3.91M Buy
57,923
+17,826
+44% +$1.17M 0.34% 39
2019
Q1 		$2.61M Buy
40,097
+10,265
+34% +$682K 0.4% 30
2018
Q4 		$1.87M Buy
+29,832
New +$2.09M 0.55% 9

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

AlphaCrest Capital Management's GILD Position: Q1 2020 in Review

AlphaCrest Capital Management sold out of Gilead Sciences (GILD) in Q1 2020, closing a stake of 110,669 shares — an estimated $7.19M sold.

AlphaCrest Capital Management first reported a position in GILD in Q4 2018 and held it in 5 quarters. The position peaked at $10.8M in Q3 2019. 1,643 funds tracked by Wall St. Rank hold GILD as of Q1 2020.

  • AlphaCrest Capital Management reported no remaining Gilead Sciences position as of Q1 2020 after selling out during the quarter.
  • AlphaCrest Capital Management sold 110,669 Gilead Sciences shares in Q1 2020, an estimated $7.19M.
  • AlphaCrest Capital Management first reported a position in Gilead Sciences in Q4 2018 and held it in 5 quarters.
  • AlphaCrest Capital Management's Gilead Sciences position peaked at $10.8M in Q3 2019.
  • 1,643 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2020.

Based on AlphaCrest Capital Management's 13F filing for Q1 2020, filed 13 May 2020.